Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study

Trial Profile

Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Doxorubicin (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ReLive
  • Sponsors BioAlliance Pharma; Onxeo SA
  • Most Recent Events

    • 11 Sep 2017 According to an Onxeo media release, the monitoring of the patients still enrolled in the study will continue to completion expected in H1 2019.
    • 11 Sep 2017 According to an Onxeo media release, the main results from the ReLive study will be presented on at the upcoming 11th Annual Conference of the International Liver Cancer Association.
    • 11 Sep 2017 Primary endpoint (Overall survival(OS) in each group) has not been met, according to an Onxeo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top